BCIM
TXG icon

British Columbia Investment Management’s 10x Genomics TXG Stock Holding History

British Columbia Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,016
Closed -$914K – 853
2022
Q1 		$914K Sell
12,016
-1,504
-11% -$132K 0.01% 786
2021
Q4 		$2.01M Sell
13,520
-159
-1% -$24.4K 0.01% 698
2021
Q3 		$1.99M Buy
13,679
+164
+1% +$28.2K 0.01% 696
2021
Q2 		$2.65M Buy
13,515
+3,007
+29% +$544K 0.02% 641
2021
Q1 		$1.9M Buy
10,508
+138
+1% +$23.8K 0.01% 677
2020
Q4 		$1.47M Buy
+10,370
New +$1.5M 0.01% 722

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

British Columbia Investment Management's TXG Position: Q2 2022 in Review

British Columbia Investment Management sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 12,016 shares — an estimated $914K sold.

British Columbia Investment Management first reported a position in TXG in Q4 2020 and held it in 6 quarters. The position peaked at $2.65M in Q2 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • British Columbia Investment Management reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • British Columbia Investment Management sold 12,016 10x Genomics shares in Q2 2022, an estimated $914K.
  • British Columbia Investment Management first reported a position in 10x Genomics in Q4 2020 and held it in 6 quarters.
  • British Columbia Investment Management's 10x Genomics position peaked at $2.65M in Q2 2021.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on British Columbia Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.